Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01086852 · ClinicalTrials.gov registry record · Phase 3
Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery
A Phase 3 study, sponsored by Bio Products Laboratory.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
NCT01086852 is a Phase 3 study that was terminated before completion, run by Bio Products Laboratory. The registered enrollment target is 4 participants.
The verdict
NCT01086852, a Phase 3 study, was terminated before completion, sponsored by Bio Products Laboratory.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
Study Summary
To primary efficacy variable is to assess the presence or absence of excessive blood loss during and after surgery. The secondary efficacy endpoints are as follows: 1. A subjective overall assessment by the investigator of FACTOR X in the control of bleeding during surgery. 2. The incidence of bleeding episodes during treatment with FACTOR X while the subject is at risk of post-operative bleeding, including location and duration. 3. Incremental recovery of FX:C and FX:Ag after the pre-surgery bolus infusion. 4. Assessment of FX:C and FX:Ag levels on each day post-surgery. 5. Assessment of the cumulative weight-adjusted doses of FACTOR X as measured by FX:C (IU/kg body weight) administered to each subject to maintain haemostasis. 6. Assessment of the cumulative doses of FACTOR X as measured by FX:C (IU) administered to each subject to maintain haemostasis. 7. Amount of weight-adjusted FACTOR X as measured by FX:C (IU/kg body weight) administered daily (day of surgery and each post-operative day) to maintain haemostasis.
Interventions
- BIOLOGICAL FACTOR X
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-03 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01086852
The ClinicalTrials.gov registry entry for NCT01086852 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bio Products Laboratory, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FACTOR X is the first listed.
NCT01086852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01086852 about?
NCT01086852 is a clinical study titled "Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery". To primary efficacy variable is to assess the presence or absence of excessive blood loss during and after surgery. The secondary efficacy endpoints are as follows: 1. A subjective overall assessment by the investigator of FACTOR X in the control of bleeding during surgery. 2. The incidence of ble...
What is the current status of trial NCT01086852?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2011-03. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01086852?
The interventions under investigation include: FACTOR X (BIOLOGICAL).
Who is sponsoring clinical trial NCT01086852?
This trial is sponsored by Bio Products Laboratory, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.